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At a cost of  $10 million, Coralville, Iowa-based Integrated DNA Technologies (IDT) has completed 
its 77,000-square-foot headquarters expan-
sion. And with it, IDT effectively doubled its 
research, support and production capacity, 
allowing it to better cater to increasing  
market demand for its products by  
enhancing its customer service and order  
fulfillment departments.
IDT is the largest supplier of  custom nucleic 
acids in the United States, serving academic 
research, biotechnology and pharmaceutical 
development industries by manufacturing the 
highest quality custom nucleic acids.  
 
“We sell short strands of  DNA called oligo-
nucleotides (oligos),” says Trey Martin, IDT 
chief  operating officer. “The way one strand 
of  DNA specifically binds to a second strand 
of  DNA allows scientists to use oligos as 
research tools. Common uses for our oligos 
include diagnostic tests for genetic diseases 
and infectious diseases, research to discover 
new drugs or therapies for a variety of   
diseases, and producing safer and more  
plentiful agricultural products.”
Founded in 1987 by Dr. Joseph Walder, IDT 
has achieved double-digit growth over the 
past 10 years. Today, the company synthesizes 
and ships more than 25,000 custom oligos 
per day, with more than 60,000 customers 
worldwide.
Integrated DNA Technologies completes 
77,000-square-foot headquarters expansion
Life sciences company building on Iowa presence, adding  
capacity and jobs
Continued on page 6
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As the need for skilled employees continues to grow, the Iowa Bio-
process Training Center (IBTC) is 
helping to train and deepen Iowa’s 
labor pool for the expanding bio-
processing industry.
“Our aim is to develop a skilled 
workforce for Iowa’s biotechnology 




two-year credit program in bioprocess 
technology of  Indian Hills Community 
College, as well as new process control 
technician and ethanol plant technician 
certificate programs. It also provides indus-
try-specific, custom-designed training to 
existing workers in the biotech field. 
Operated by Iowa BioDevelopment, the 
IBTC is a public-private initiative located 
at Eddyville’s Iowa Bioprocessing Center 
complex. Partners in the training center’s 
design and financing include the Iowa 
Department of  Economic Development 
(IDED), Cargill, Ajinomoto Food Ingredients, Ajinomoto 
Heartland, Wapello, Mahaska, and Monroe counties,  
plus others. 
As one of  the five U.S. Department of  Labor-designated Cen-
ters of  Excellence for Biotechnology, IBTC is a 13,000-square-
foot training facility that contains a fermentation pilot plant, 
a virtual reality fermentation center, process control training 
modules and classrooms. 
“Job opportunities for those who complete our bioprocess 
program exist worldwide. In fact, 98 percent of  our gradu-
ates have found employment opportunities with biotechnology 
companies,” says Crabtree, adding that the graduates typically 
start at an annual salary in excess of  $30,000. 
Crabtree says one need look no further than Eddyville’s Iowa 
Bioprocessing Center to see how value-added agriculture and 
biotechnology are transforming Iowa. Anchored by Cargill’s 
massive corn wet-milling operation, five multinational com-
panies are producing a myriad of  value-added products from 
Iowa corn and soybeans. 
Since 1985, when Cargill opened its operation, companies 
such as Ajinomoto Food Ingredients, Wacker Chemical Cor-
poration, EPCO Carbon Dioxide Products, and Ajinomoto 
Heartland LLC have made capital investments of  more than 
$1.2 billion and created jobs for nearly 800 Iowans. 
Iowa’s rapidly expanding renewable fuels industry also holds 
increasing opportunities for a highly skilled workforce. The 
Iowa Renewable Fuels Association says 
that by the end of  2006, Iowa will have 
a minimum of  28 ethanol plants as well 
as eight biodiesel facilities. This makes 
Crabtree all the more excited about the 
pilot facility at IBTC and its numerous 
research scale fermenters. 
“Our 13-liter and 150-liter fermenters 
can be used by start-up life sciences 
companies for research or optimization 
purposes,” explains Crabtree. “The 
equipment is designed to mimic on a 
smaller scale what would happen in the 
industrial fermentation arena.” 
The virtual reality model, designed by Iowa State University, 
is used to educate students and industry staff  on the effects of  
changing fermentation parameters on the production of  citric 
acid. “A seven- to 10-day fermentation run can be  
virtually modeled in seconds, pro-
viding valuable hands-on, real life 
problem solving experiences for 
students,” says Crabtree. 
By providing hands-on training of  
existing and future biotechnology 
workers in a state-of-the-art facil-
ity, Indian Hills’ IBTC is helping 
fuel the growth of  bioprocessing 
firms in Iowa now and into the 
future.   ■
BioTech training at specialized Iowa unit
3Iowa’s Kemin Industries develops new market 
opportunity in functional foods  
Kemin Industries Inc., a  Des Moines-based pro-vider of  nutritional ingre-
dients solutions, has created a new  
division—Kemin Food Ingredients 
(KFI)—to market superior shelf-life 
solutions that preserve the freshness 
and enhance the quality of  food.   
The division will be based in  
Des Moines, Iowa.  
“Iowa is a hub for agriculture, 
health and food industries and 
offers a very high caliber of  scien-
tific talent,” says Chris Nelson,  
president of  Kemin Industries, 
“This allows Kemin to very effec-
tively advance molecular discovery 
and create products for the func-
tional foods market in addition to 
our other markets.”  
Kemin Industries, Inc., which has 
been enjoying a 10-year run of  
double-digit sales growth while 
venturing into many new markets, 
is in the midst of  a $17.8 million 
headquarters expansion, leveraged 
by a $550,000 Iowa Values Fund 
award from the Iowa Department 
of  Economic Development.  
“Phase-one of  Kemin’s expansion 
is underway and will enable expan-
sion of  our innovation center as 
well as additional production capac-
ity, bringing new jobs to Kemin’s 
Des Moines location,” says Nelson.  
The newly created KFI will lever-
age Kemin’s expansion as the group 
prepares for rapid global growth 
and new product and category 
development to drive long-term 
expansion.  
“KFI will introduce a ‘Functional 
Foods Ingredients’ platform in 
2006 and the first entry will be 
FloraGLO® brand lutein, which 
we will market to the food and bev-
erage industries,”  says K.P. Philips, 
president of  the division.    
Functional foods refer to ordinary 
foods that contain or have been 
enriched with health-promoting 
ingredients, as well as foods that 
may provide health, immunity or 
disease-fighting benefits beyond 
their existing value to daily  
nutrition.  
For example, KFI’s FloraGLO® 
lutein, made from marigold  
petals, can help prevent macular 
degeneration, a leading cause of  
blindness.  Current KFI product 
lines that help conserve the fla-
vor, color and nutritional value of  
food include FORTIUM® brand 
natural antioxidants and extracts, 
SHIELD® brand antimicrobial  
systems and EN-HANCE™  
brand synthetic antioxidants.    
Over the next several years, 
researchers anticipate the functional 
foods (also known as nutraceuti-
cals) market may increase an aver-
age of  9.9 percent annually.  Fry 
Foods International estimates the 
total market for functional foods 
in Japan, Europe and the United 
States at approximately $38 billion.  
Imagine a drink that may help pre-
vent blindness, breads and tortillas 
that can stay fresh for months, or 
foods that can improve skin health 
and keep certain cancers at bay. 
Every day the nutritional ingredient 
experts at Iowa’s Kemin Industries 
strive to turn these dreams into 
reality by developing an  
ever-expanding array of   
nutraceutical products.  ■
 
4In Ames, Iowa, BioForce Nanosciences Inc., is poised to add manufac-
turing jobs due to continued mar-
ket demand for its nanotechnology 
equipment. 
According to Eric Henderson, 
BioForce founder and CEO, the 
company started out as a supplier 
of  accessories in Atomic Force 
Microscopy. 
“Today, we are providing products 
and services that allow researchers 
to work in ultra-miniaturized scale 
— where one nanometer equals 
one billionth of  a meter, and one 
human hair measures 200,000 
nanometers in diameter,” says 
Henderson. 
BioForce’s patented product, the 
NanoArrayer™, is the centerpiece 
of  the company’s products and 
technologies. 
Designed for biomedical purposes and 
costing upwards of  $125,000, “The 
NanoArrayer System allows researchers 
to run many tests with very little mate-
rial—from a small sample of  spinal fluid 
or a newborn’s blood,” says Henderson. 
“The NanoArrayer allows scientists to 
view and track as many as 1,500 differ-
ent samples at once. Previously, research-
ers were restricted to viewing one sample 
at a time,” he continues. 
Depending on the type of  research, the 
NanoArrayer can capture molecular 
reactions for cancer/disease screening, 
drug development, water and air testing, 
agricultural and industrial situations, and 
many other applications. 
BioForce is now collaborating with Iowa 
State University (ISU) to develop a  
sensitive nanotechnology-based method 
for detecting food-borne pathogens. 
“We will focus on the combination of  
nanotechnology and molecular biology 
to create a new and powerful platform 
for pathogen detection in foods,” says 
Henderson, who is a professor of  genet-
ics and cell biology at ISU. 
The company also has research col-
laborations and grants with the U.S. 
Department of  Defense to find new ways 
to detect bioterror agents and with the 
National Cancer Institute and the Food 
and Drug Administration to apply  
nano-technology to the screening of  
ovarian cancer. 
Other BioForce products include its 
ViriChip System, a proprietary ultra-
micro detection system for viruses. “The 
ViriChip silicon wafer can be so small 
as to be invisible to the naked eye,” says 
Henderson. “It holds testing agents that 
could help identify biological threats 
such as anthrax, sarin and small-
pox.” 
In the fall of  2005, BioForce was 
awarded $500,000 from the Iowa 
Department of  Economic Develop-
ment to help the company  
commercialize its technology. 
“BioForce has followed the tried 
and true model of  beginning with 
a vision, then working for funding 
through grants, seed capital and 
other sources to fund research on na-
scent technology,” says Henderson. 
“After 11 years, we are now reaching 
our long-term goal of  bringing new 
and innovative products to market.” 
It’s ironic to consider that nanosci-
ence, the technology that allows 
scientists to look at materials on the 
atomic and molecular level, is truly 
becoming the next “big” thing. 
In Ames, 17-employee BioForce is using 
its 11 years of  experience in nanotech-
nology and molecular biology to produce 
a series of  proprietary products for its 
pharmaceutical, veterinary, government 
and education customers. 
“With new products and services being 
developed all the time, we anticipate 
doubling our employment in the next 
year. We could even see spin-off  busi-
nesses result as we focus on our specialty 
markets,” says Henderson.
For more information on how  
an Iowa location can help your  
company secure huge returns, call 
an Iowa Department of  Economic 
Development project manager 
for a confidential consultation at 
800.245.IOWA (4692), or visit  
www.iowalifechanging.com.  ■
Nanotechnology is Huge at Iowa’s BioForce
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Genencor International, a leading industrial biotechnology company 
that develops and produces en-
zymes for the bioproducts mar-
ket, is in the midst of  a $35-mil-
lion expansion at its production 
facility in Cedar Rapids, Iowa. 
“Through the expansion, Genen-
cor plans to establish Cedar Rap-
ids as its prime manufacturing 
operation for North America,” 
says Frans Van Londersele, plant 
manager of  the Cedar Rapids 
facility. “When completed in 
2008, the expansion will double 
the current capacity of  the plant 
and allow us to maintain our po-
sition as the preeminent supplier 
of  enzymes and bioproducts for 
the ethanol, cleaning, textiles and 
chemical industries.”
“While the new expansion  
project was recruited by  
communities across the U.S.,  
a number of  options and  
criteria were compared, including manufacturing and opera-
tional costs, process performance and future capital investment 
needed in Genencor plants within the United States,” Van 
Londersele says. “Looking at all that, and the incentives of-
fered, the best option was to expand in Cedar Rapids.”
The expansion project, which creates 17 new jobs and re-
tains 80 jobs at an average hourly wage of  $20.37, received a 
$750,000 Public Infrastructure Assistance Program award  
from the Iowa Department of  Economic Development. The 
expansion was also approved for Enterprise Zone tax benefits.
The enzymes produced by Genencor are proteins that help a 
chemical reaction take place specifically, quickly and efficiently, 
and offer a number of  environmental and worker safety  
advantages by replacing harsh  
chemicals or processes in many 
manufacturing operations. “For  
example, the use of  industrial  
enzymes replaces acids and  
chemicals in the starch, paper and 
textiles, and other production pro-
cesses,” explains Van Londersele.
Genencor, a division of   
Copenhagen-based Danisco A/S, 
built its greenfield production facil-
ity in Cedar Rapids in 1989. Since 
that time, its industrial enzymes 
have been used by laundry and dish 
detergent makers and in the grain 
processing and ethanol industries.
“Additionally, grain millers use our 
enzymes to convert the starch in 
corn, wheat and tapioca grains into 
value-added food and industrial 
ingredients,” says Van Londersele. 
“Our team of  professionals also 
provide applications expertise and 
technical support to customers.”
In fact, Genencor’s newest product, 
STARGEN™, was named in R&D Magazine’s Top 100 Most 
Technological Significant Products. STARGEN is an enzyme 
that significantly reduces the number of  steps and costs in  
producing ethanol. “The potential advantages of  our  
STARGEN technology to our customers include improved  
productivity, reduced energy consumption, higher ethanol 
yields and savings on capital expenses by reducing overall  
unit operations,” says Van Londersele. 
And Iowa’s booming renewable fuels industry stands ready to 
take advantage of  the technology. The Iowa Renewable Fuels 
Association says that by the end of  2006, the state will have a mini-
mum of  28 ethanol plants capable of  annually producing more 
than 1.8 billion gallons of  the corn-based fuel.   ■ 
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Genencor International expanding its  
Cedar Rapids, Iowa facility
$35 million expansion establishes Cedar Rapids as prime North American manufacturing operation
Genencor was named to  
R&D Magazine’s Top 100 Most 
Technological Significant Products 
for development of its STARGEN™ 
enzyme that significantly reduces 
the number of steps and costs in 
producing ethanol. 
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Cellular Engineering Technologies 
(CET), located at the University 
of  Iowa’s Technology Innovation 
Center (TIC), has announced it is 
the first Iowa company to operate 
a robotic stem cell separator. The 
equipment will provide a vast array 
of  opportunities for tissue and dis-
ease research.
Founded in 2000 by Dr. Alan Moy, a 
physician-scientist-professor from the 
UI Department of  Internal Medicine 
and Biomedical Engineering, CET is 
commercializing technologies devel-
oped at the university and licensed 
from the UI Research Foundation.
The company will use the stem cell 
separator to build upon its collabo-
rations with researchers at the UI, 
Iowa State University, Harvard and 
the University of  Tennessee among 
others.
CET’s $50,000 Robosep uses two 
high-powered magnets to bind stem 
cells with an antibody. “The machine 
then isolates the cell from its originat-
ing blood, isolating any immunologi-
cal cell from either umbilical cord 
blood or adult blood,” says Moy. 
“The possibilities for tissue engi-
neering and tissue development are 
endless.”
Stem cells are master cells that have 
the potential to develop into any cell 
type in the body. Scientists believe 
they could act as a type of  repair 
system to provide new therapies for 
illnesses ranging from diabetes to 
Parkinson’s.
Stem-cell research is controversial, 
with many scientists believing the 
most promising stem cells for treating 
human diseases are derived from em-
bryos left over from fertility clinics.
CET does not conduct embryonic 
stem cell research, which is banned 
in Iowa. “Use of  adult stem cells is 
more attractive from the standpoint 
of  logistics and business economics,” 
says Moy. 
“Adult-derived stem cells have 
produced the same types of  special-
ized cells as embryonic stem cells. It 
would be preferable to use a patient’s 
own stem cells because it eliminates 
the risk of  tissue rejection.”
Adult tissues that contain stem cells 
include brain, bone marrow, periph-
eral blood, blood vessels, skeletal 
muscle, skin and liver. A stem cell is 
100,000 times smaller than the thick-
ness of  a strand of  hair.
Once CET isolates the cells, they are 
treated with different growth factors, 
grown in an incubator and then 
evaluated for their response.
“We research and develop therapeu-
tic, research and clinical diagnostic 
tools to evaluate complex physiologi-
cal responses in living cells, stem cells 
and tissue,” explains Moy. “The 
results can be used to better un-
derstand pharmaceutical drugs’ or 
genes’ effects on cell functions.”
Along with providing precise infor-
mation on how drugs or genes affect 
human or animal cell function or 
how biological molecules alter cel-
lular mechanics, Moy says he wants 
CET “to show that high-tech stem 
cell work is happening in Iowa.
“Universities, researchers and other 
biotechnology companies do not 
have to outsource stem cell isolation 
and testing to other states,” says Moy. 
CET is one of  nearly 90 high- 
technology companies that have 
been admitted to the TIC since the 
business incubator was established  
in 1984.    ■
CET Research in Iowa may stem disease
Completion of  IDT’s new headquarters will allow 
the company to increase its current employment 
base of  338 by up to 50 percent over the next two 
years, says Martin. 
“Coralville is the heart and soul of  IDT,” he says. 
“From here we’ve become the supplier of  choice 
for biotech labs all around the world, serving re-
searchers across every time zone and across every 
area of  biological study. Our expanded facility 
serves to strengthen our deep roots in Iowa, and 
shows our commitment to the state’s future.”
Iowa has reciprocated that commitment. The 
expansion project was awarded $600,000  
from the Iowa Department of  Economic  
Development’s Community Economic  
Betterment Account. 
With the completed expansion project—IDT’s 
fourth expansion since its founding—Martin 
says the company will build upon its strength as 
the largest supplier of  custom nucleic acids in 
the U.S. “Our plans are to enter the European 
market, acquire competing custom-oligo manu-
facturers, and roll out more and more proprietary 
products to keep Integrated DNA on the leading 
edge of  life science research,” he says.
If your bioscience company would like 
confidential assistance with an expansion, 
contact the Iowa Department of Economic 
Development at 800.245.IOWA (4692).   ■
Integrated DNA 
 — Continued from page 1
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Previously, to test for bacteria or 
pathogens in liquids, purified water  
and drinking water, samples would be 
placed on culture plates and placed in 
an incubator for up to 48 hours to see if  
a pathogen or bacteria would grow.
“Companies need to be able to move 
products faster and get test results more 
quickly, so we knew there was a need 
for rapid bacterial detection technol-
ogy,” say Lasky.
AATI’s technology uses flow cytrometry 
to detect bacteria in a sample. “Flow 
cytometry is a technology that counts 
individual, micron sized particles such as 
bacteria or yeast as they pass through a 
beam of  laser light,” explains Lasky.
AATI’s latest detector, the RBD3000 is a 
patent-protected instrument that’s totally 
automated, can test up to 42 samples in 
quick succession and requires little  
training to operate.
“After liquid samples are loaded into  
the RBD 3000, its robotic arms add a 
fluorescent tag to each sample that ad-
heres to the bacteria,” explains Lasky.
“Each sample is mixed and incubated 
for a short period of  time before it 
passes through a laser beam. Any living 
bacteria will glow when the laser hits it, 
and the machine electronically counts 
and records each type of  pathogen and 
its intensity.”
With more and more companies discov-
ering the advantages of  the RBD 3000, 
the company is adding staff  that will 
help it produce new products. AATI was 
heavily recruited by states on both coasts 
and the upper Midwest for the expan-
sion project, but Lasky says its Iowa 
location has advantages.
“The advantage of  Iowa really comes 
down to work ethic,” he says. “Out of  
all the states I’ve worked in, I’ve never 
seen such a committed staff. Ties to 
Iowa State University have also been 
helpful, with access to their research and 
scientific staff. More importantly, we’ve 
been able to work with John Poppajohn 
and companies like the Principal Finan-
cial Group and Farm Bureau Financial 
Group that have invested in us and 
stayed behind us,” Lasky says.
AATI’s expansion also received  
$2 million in awards from the Iowa  
Department of  Economic Development. 
In return, the company pledges to create 
45 technology jobs and retain 35 existing 
positions.
Founded in 1998, AATI has weath-
ered the many storms associated with 
high-technology start up companies. 
But through it all, the company had the 
backing of  partners in the venture  
capital field, the university research  
arena and a supportive state  
government.
Now poised for great success, AATI is  
creating high-quality, high-paying jobs 
as well as helping build critical mass in 
the state’s scientific and technology  
industries.   ■
Partnerships lead to growth at Iowa’s AATI
bu s i n e s s p h e r e
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Technology developed at Advanced  Analytical Technologies, Inc. (AATI) is finding increased market 
acceptance in a wide range of  industries.
With that acceptance is an expansion of  
manufacturing jobs at the Ames, Iowa-
based company. The technology – a rapid 
bacteria detector (RBD) – is in demand in 
the pharmaceutical, food and beverage, 
and cosmetic and personal care industries.
“Companies like Procter & Gamble  
and Alberto-Culver Co., are using our 
technology because of  the speed and  
accuracy in detecting pathogens and  
microbes in water and other liquids,”  
says Steve Lasky, AATI founder,  
president and CEO.
Companies and manufacturers in  
the pharmaceutical and cosmetics  
industries are required to run a series of  
quality-assurance tests on their products 
before shipping them to market.
 It was more than 45 years ago that my  
parents R.W. and Mary Nelson founded  
Kemin Industries in Des Moines, Iowa. While 
Kemin began as a manufacturer of  animal feed 
ingredients, we’ve evolved to become nutritional 
ingredient experts for human dietary supple-
ments, pet foods and newly introduced food 
products as well.  Serving a customer base that 
impacts 80 percent of  the global food production 
capability, Kemin Industries strives to touch the 
lives of  people in the world every day through 
our products and services.  
As we strive to increase our share in the many 
markets that Kemin serves and as we continue to 
make molecular discoveries that have widespread 
application potential, we have a powerful new 
partner to help assist our efforts.  Iowa’s biosci-
ence companies have joined together  
with state university partners to form the 
Biosciences Alliance of  Iowa (BAI).  
As inaugural chair of  BAI’s executive commit-
tee, I am excited to help promote BAI’s role as 
an advisory committee to the Iowa Department 
of  Economic Development to focus state efforts 
in key agricultural, medical and plant bioscience 
areas. Our membership represents science, indus-
try, education, medicine, agriculture, economic 
development and government entities. Our goal 
is to pool resources to develop new bio-based 
businesses in the state.  
Using financial resources flowing to BAI, we 
have approved $700,000 in state funds to Iowa 
State University’s Center for Designing Foods to 
Improve Nutrition. Another $450,000 was award-
ed to the University of  Iowa for equipment and 
software for advanced genomics research, with an 
additional $500,000 to UI for the creation of  a 
disease research center where bioscience compa-
nies can create animal models of  human diseases.
Projects such as these support multiple businesses, 
not only nascent businesses growing around the 
universities, but throughout the state. World-
renowned for their dynamic research capabili-
ties in the plant, animal and human biosciences, 
Iowa’s three public universities are welcoming 
partnerships with businesses on applied research 
projects. With BAI’s support, Iowa companies will 
direct more research activity to the universities 
in the years ahead and work more closely with 
the scientific talent we have in the state. BAI also 
works to bolster existing collaborations between 
industry and Iowa’s research institutions, and 
continually mines university research for  
marketable products.  
The biosciences industry significantly impacts 
Iowa’s economy. Kemin, Integrated DNA 
Technologies, Archer Daniels Midland Co., 
Roquette America, Cargill, Monsanto and 
DuPont’s Pioneer Hi-Bred International are 
only a few of  Iowa’s 1,800 bioscience companies 
employing more than 83,000 people. 
Everyday, Kemin and other Iowa life sciences 
companies seek to commercialize new bioscience 
innovations. Together with Iowa’s  
outstanding business climate, a skilled, well- 
educated and adaptable workforce, and an  
enviable quality of  life, Iowa is providing  
bioscience companies with an exciting new 
resource to assist us in our endeavors:  
The Biosciences Alliance of  Iowa.   ■
g u e s t  o p i n i o n
Working together, Iowa’s bioindustry and  
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